Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
TransMedics participates in a conference call with Cowen » 16:02
04/12/21
04/12
16:02
04/12/21
16:02
TMDX

TransMedics

$28.61 /

-3.14 (-9.89%)

Healthcare Analyst…

Healthcare Analyst Jennings holds a conference call with management on April 19 at 1 pm hosted by Cowen.

ShowHide Related Items >><<
TMDX TransMedics
$28.61 /

-3.14 (-9.89%)

TMDX TransMedics
$28.61 /

-3.14 (-9.89%)

04/07/21 Canaccord
TransMedics label likely more limited than expected, says Canaccord
03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
TMDX TransMedics
$28.61 /

-3.14 (-9.89%)

  • 27
    May
TMDX TransMedics
$28.61 /

-3.14 (-9.89%)

Over a week ago
On The Fly
Fly Intel: Pre-market Movers » 08:57
04/07/21
04/07
08:57
04/07/21
08:57
CAHC

CA Healthcare Acquisition

$9.65 /

+ (+0.00%)

, TMDX

TransMedics

$34.41 /

+0.1 (+0.29%)

, HYLN

Hyliion Holdings

$10.86 /

+0.11 (+1.02%)

, HIMX

Himax

$14.44 /

+0.25 (+1.76%)

, SMPL

Simply Good Foods

$31.21 /

-0.17 (-0.54%)

, MSM

MSC Industrial

$91.77 /

-0.065 (-0.07%)

, RPM

RPM

$94.30 /

+0.21 (+0.22%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

, FIXX

Homology Medicines

$9.30 /

-0.34 (-3.53%)

, UPST

Upstart

$143.99 /

+3.03 (+2.15%)

Check out this morning's…

ShowHide Related Items >><<
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

04/07/21 Canaccord
TransMedics label likely more limited than expected, says Canaccord
03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

03/18/21 UBS
Hyliion Holdings initiated with a Neutral at UBS
02/02/21 Goldman Sachs
Hyliion Holdings downgraded to Sell from Neutral at Goldman Sachs
12/16/20 Barclays
Hyliion Holdings initiated with an Overweight at Barclays
10/28/20
Fly Intel: Top five analyst initiations
HIMX Himax
$14.44 /

+0.25 (+1.76%)

03/09/21 Vertical Group
Himax reinstated with a Neutral at Vertical Group
02/08/21 Northland
Himax price target raised to $13 from $4.50 at Northland
01/27/21 Nomura
Himax upgraded to Buy from Neutral at Nomura
11/30/20 Baird
Himax price target raised to $11 from $8 at Baird
SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

04/06/21 Credit Suisse
Simply Good Foods initiated with a Neutral at Credit Suisse
03/19/21 Jefferies
Simply Good Foods downgraded to Hold on valuation at Jefferies
03/19/21 Jefferies
Simply Good Foods downgraded to Hold from Buy at Jefferies
02/03/21 DA Davidson
Simply Good Foods downgraded to Neutral from Buy at DA Davidson
MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

04/05/21 Deutsche Bank
MSC Industrial price target lowered to $89 from $90 at Deutsche Bank
01/07/21 Wells Fargo
MSC Industrial price target raised to $90 from $80 at Wells Fargo
12/31/20 William Blair
Azek, Trex among Blair's top Specialty Distribution ideas for 2021
12/16/20 Deutsche Bank
MSC Industrial price target raised to $92 from $75 at Deutsche Bank
RPM RPM
$94.30 /

+0.21 (+0.22%)

03/04/21 Vertical Research
RPM upgraded to Buy from Hold at Vertical Research
01/08/21 RBC Capital
RPM downgraded to Sector Perform from Outperform at RBC Capital
01/07/21 BMO Capital
RPM price target raised to $113 from $109 at BMO Capital
12/14/20 Morgan Stanley
RPM downgraded to Equal Weight from Overweight at Morgan Stanley
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
UPST Upstart
$143.99 /

+3.03 (+2.15%)

03/22/21 Barclays
Upstart price target raised to $110 from $58 at Barclays
03/18/21 BofA
Upstart upgraded to Buy on accelerating growth at BofA
03/18/21 BofA
Upstart upgraded to Buy from Neutral at BofA
03/18/21
Fly Intel: Top five analyst upgrades
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

  • 09
    Apr
  • 07
    Apr
  • 16
    Dec
  • 27
    May
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Recommendations
TransMedics label likely more limited than expected, says Canaccord » 08:34
04/07/21
04/07
08:34
04/07/21
08:34
TMDX

TransMedics

$34.41 /

+0.1 (+0.29%)

Canaccord analyst William…

Canaccord analyst William Plovanic noted the FDA panel voted in favor of recommending approval for the TransMedics OCS Heart PMA after a contentious discussion of the data supporting the safety, efficacy, and ultimate risk/benefit of the device. As a result, the analyst believes the IFU label will be a bit more restrictive than anticipated. Plovanic maintains his Buy rating and $79 price target on TransMedics shares.

ShowHide Related Items >><<
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

  • 27
    May
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

Hot Stocks
TransMedics announces FDA advisory committee vote in favor of OCS Heart System » 05:41
04/07/21
04/07
05:41
04/07/21
05:41
TMDX

TransMedics

$34.41 /

+0.1 (+0.29%)

TransMedics announced…

TransMedics announced that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the FDA has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2. The panel voted 12 to 5, with one abstaining, that the benefits of the OCS Heart System outweigh its risks. The panel voted 10 to 6, with two abstaining, that there is reasonable assurance that the OCS Heart System is effective. The panel voted 9 to 7, with two abstaining, that there is reasonable assurance of the OCS Heart System's safety.

ShowHide Related Items >><<
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

  • 27
    May
TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

Conference/Events
FDA Circulatory System Devices Panel holds a virtual meeting » 08:50
04/06/21
04/06
08:50
04/06/21
08:50
TMDX

TransMedics

$34.41 /

-5.48 (-13.74%)

The Committee discusses,…

The Committee discusses, makes recommendations and votes on information regarding TransMedics' Premarket Approval Application for the TransMedics Organ Care System (OCS) Heart, a portable extracorporeal heart perfusion and monitoring system in a virtual meeting to be held on April 6 at 9 am. Webcast Link

ShowHide Related Items >><<
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

  • 27
    May
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

Hot Stocks
TransMedics trading halted, FDA Advisory panel to review OCS Heart System » 07:07
04/06/21
04/06
07:07
04/06/21
07:07
TMDX

TransMedics

$34.41 /

-5.48 (-13.74%)

TransMedics announced…

TransMedics announced that Nasdaq has halted trading of the company's common stock. The U.S. FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee is meeting April 6 to review TransMedics' Organ Care System Heart System. The OCS Heart System is a portable organ perfusion and monitoring medical device intended to preserve a donated heart in a near-physiologic, beating and perfused state, while continually monitoring and optimizing heart function for eventual transplantation into the recipient. The Advisory Committee meeting is scheduled for 9:00 a.m. ET.

ShowHide Related Items >><<
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

  • 27
    May
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

Hot Stocks
TransMedics Group trading halted, news pending  06:55
04/06/21
04/06
06:55
04/06/21
06:55
TMDX

TransMedics

$34.41 /

-5.48 (-13.74%)

 
ShowHide Related Items >><<
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

  • 27
    May
TMDX TransMedics
$34.41 /

-5.48 (-13.74%)

Recommendations
TransMedics price target raised to $49 from $44 at Cowen » 08:15
03/29/21
03/29
08:15
03/29/21
08:15
TMDX

TransMedics

$39.74 /

-1.82 (-4.38%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings raised the firm's price target on TransMedics to $49 from $44 and keeps an Outperform rating on the shares. The analyst expects a positive panel partly thanks to Expand continued access program's greater role in the filing after the pandemic delays. He said he knows that Expand CAP enhances Expand's strong standalone findings.

ShowHide Related Items >><<
TMDX TransMedics
$39.74 /

-1.82 (-4.38%)

TMDX TransMedics
$39.74 /

-1.82 (-4.38%)

03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
03/02/21 Oppenheimer
TransMedics price target raised to $40 from $25 at Oppenheimer
TMDX TransMedics
$39.74 /

-1.82 (-4.38%)

  • 27
    May
TMDX TransMedics
$39.74 /

-1.82 (-4.38%)

Over a month ago
Recommendations
TransMedics price target raised to $79 from $46 at Canaccord » 08:14
03/15/21
03/15
08:14
03/15/21
08:14
TMDX

TransMedics

$36.33 /

-0.98 (-2.63%)

Canaccord analyst William…

Canaccord analyst William Plovanic raised the firm's price target on TransMedics to $79 from $46 and keeps a Buy rating on the shares. The analyst believes they have the technology that will become the standard of care for organ transplant and in the process, facilitate a significant increase in the supply of implantable donated organs to address excess demand.

ShowHide Related Items >><<
TMDX TransMedics
$36.33 /

-0.98 (-2.63%)

TMDX TransMedics
$36.33 /

-0.98 (-2.63%)

03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
03/02/21 Oppenheimer
TransMedics price target raised to $40 from $25 at Oppenheimer
02/24/21 Cowen
TransMedics price target raised to $44 from $20 at Cowen
TMDX TransMedics
$36.33 /

-0.98 (-2.63%)

  • 27
    May
TMDX TransMedics
$36.33 /

-0.98 (-2.63%)

Recommendations
TransMedics price target raised to $38 from $16 at Morgan Stanley » 09:40
03/03/21
03/03
09:40
03/03/21
09:40
TMDX

TransMedics

$39.55 /

+0.025 (+0.06%)

Morgan Stanley analyst…

Morgan Stanley analyst David Lewis raised the firm's price target on TransMedics to $38 from $16 and keeps an Equal Weight rating on the shares. The analyst believes the company "weathered 4Q well" and he's encouraged by OCS Lung's traction and management's 2021 guidance. Lewis sees the heart and liver FDA panels dictating the share performance this year. He expects mixed panel documents for heart but is optimistic that continued access protocol data will "alleviate any concerns."

ShowHide Related Items >><<
TMDX TransMedics
$39.55 /

+0.025 (+0.06%)

TMDX TransMedics
$39.55 /

+0.025 (+0.06%)

03/03/21 Canaccord
TransMedics price target raised to $46 from $20 at Canaccord
03/02/21 Oppenheimer
TransMedics price target raised to $40 from $25 at Oppenheimer
02/24/21 Cowen
TransMedics price target raised to $44 from $20 at Cowen
10/08/20
Fly Intel: Top five analyst downgrades
TMDX TransMedics
$39.55 /

+0.025 (+0.06%)

  • 27
    May
TMDX TransMedics
$39.55 /

+0.025 (+0.06%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.